2. Academic Validation
  3. In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China

In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China

  • Antimicrob Agents Chemother. 2017 Jan 24;61(2):e02008-16. doi: 10.1128/AAC.02008-16.
Ken B Waites 1,  Donna M Crabb 2,  Lynn B Duffy 2,  Jorgen S Jensen 3,  Yang Liu 4,  Susanne Paukner 5
Affiliations

Affiliations

  • 1 Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA kwaites@uabmc.edu.
  • 2 Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • 3 Sexually Transmitted Bacterial Infections, Research and Development, Statens Serum Institut, Copenhagen, Denmark.
  • 4 Institute of Antibiotics, Huashan Hospital, Fudan University, and China Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
  • 5 Nabriva Therapeutics AG, Vienna, Austria.
PMID: 27855075 DOI: 10.1128/AAC.02008-16
Abstract

Lefamulin, an investigational pleuromutilin, was tested against a collection of 18 macrolide-susceptible and 42 macrolide-resistant Mycoplasma pneumoniae strains, and the results were compared with those of azithromycin, erythromycin, Tetracycline, doxycycline, and moxifloxacin testing. Lefamulin was highly active against all strains tested, with all MICs at ≤0.008 μg/ml. The lefamulin MIC90 (0.002 μg/ml) for macrolide-resistant strains was the lowest among all drugs tested. Minimum bactericidal concentrations were within 2 dilutions of the MIC values, indicating a bactericidal effect.

Keywords

Mycoplasma pneumoniae; lefamulin; pleuromutilin; pneumonia; susceptibility testing.

Figures
Products